Navigation Links
Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
Date:5/29/2012

MENLO PARK, Calif., May 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced that it has filed a "shelf" registration statement with the Securities and Exchange Commission. This will replace the Company's previously filed shelf registration statement, which will expire in June 2012 and includes the registration for the sale of common stock, preferred stock or debt securities.

The Company currently has no plan to issue any securities under the registration statement, and the terms of any future offering pursuant to the registration statement would be established at the time of the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise ® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

CONTACT: August J. Moretti

Depomed, Inc.

650-462-5900

amoretti@depomed.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Jefferies 2012 Global Health Care Conference
2. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
3. New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed
4. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
5. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
6. Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
7. Watson Announces Lidoderm® Patent Challenge Settlement
8. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
10. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
11. Uroplasty Announces Product Development and New Clinical Trial Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “When the ... Lead Home” is the creation of published author Laura Weigel Douglas, an avid reader ... cat in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):